Bruton tyrosine kinase inhibitors (BTKi) have transformed the therapeutic landscape of
chronic lymphocytic leukaemia (CLL) and non‐Hodgkin lymphoma. However, primary and …

Bruton tyrosine kinase (BTK), a mediator of B‐cell receptor (BCR) signalling, has been
implicated in the pathogenesis of chronic lymphocytic leukaemia (CLL) and other B‐cell …

Simple Summary Non-covalent Bruton's tyrosine kinase inhibitors (ncBTKi) are being
investigated for the treatment of B-cell malignancies, including chronic lymphocytic leukemia …

Bruton's tyrosine kinase (BTK), a mediator in B cell receptor signaling has been successfully
exploited as a therapeutic target in treatment of chronic lymphocytic leukemia/small …

Ibrutinib is the first Bruton's tyrosine kinase (BTK) inhibitor, which showed significant clinical
activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) …

Simple Summary The development of drugs that successfully target Bruton tyrosine kinase
(BTK) represents a major scientific and clinical advance for the treatment of chronic …

Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective
for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas …

Abstract Purpose of Review While the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib has
revolutionized the treatment of chronic lymphocytic leukemia (CLL), current limitations …

Simple Summary The availability of Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has
undoubtedly reshaped the initial management of chronic lymphocytic leukemia (CLL) …

Covalent inhibitors of Bruton tyrosine kinase (BTK) have transformed the therapy of chronic
lymphocytic leukemia (CLL), but continuous therapy has been complicated by the …